Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
The bromodomain and extraterminal (BET) protein BRD2-4 inhibitors hold therapeutic promise in preclinical models of hematologic malignancies. However, translation of these data to molecules suitable for clinical development has yet to be accomplished. Herein we expand the mechanistic understanding o...
| Principais autores: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado em: |
American Society of Hematology
2014
|